TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers

Conditions:   Hepatocellular Carcinoma;   Metastatic Castration Resistant Prostate Cancer;   Renal Cell Carcinoma;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Squamous Cell Carcinoma of Head and Neck;   Triple-Negative Breast Cancer;   Urothelial Carcinoma;   Cholangiocarcinoma;   GastroEsophageal Cancer;   Pancreatic Cancer;   Sarcoma
Interventions:   Drug: Part 1 TPST-1120;   Drug: Part 2a TPST-1120 + nivolumab;   Drug: Part 2b TPST-1120 + docetaxel;   Drug: Part 2c TPST-1120 + cetuximab;   Drug: Part 3 TPST-1120;   Drug: Part 4a TPST-1120 + nivolumab;   Drug: Part 4b TPST-1120 + docetaxel;   Drug: Part 4c TPST-1120 + cetuximab
Sponsor:   Tempest Therapeutics
Not yet recruiting

http://bit.ly/2G8dbMR